Real-world study shows using Giotrif®/Gilotrif® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC
GioTag is the first global, real-world study to evaluate the sequencing of targeted treatments in patients with the most common acquired treatment resistance mutation1 Results published today in F......
最新文章
【不專業地下電台EP3】原來雞精是這個成分在給元氣！不愛雞精味竟然有這樣的取代方式？雞湯、雞精、滴雞精、熬雞精跟素雞精有什麼差別？ | 健談havemary.com - 圖解健康生活大小事
排便不順使糞便囤積、腸道壞菌增多 皮膚跟著惡性循環怎麼解？ | 健談havemary.com - 圖解健康生活大小事
十男九痔！男生真的容易得痔瘡？ 專業醫師痔瘡迷思大解析 | 健談havemary.com - 圖解健康生活大小事
12星座減重出新招？大餐前孅來一粒 竟可少25%油脂攝入 | 健談havemary.com - 圖解健康生活大小事
你是容易有痔瘡的人嗎？ 有這些特性的人要注意！ | 健談havemary.com - 圖解健康生活大小事
